

ATHEROGENICS INC  
Form 8-K  
February 16, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **February 16, 2005**

**ATHEROGENICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Georgia**  
(State or other jurisdiction  
of incorporation)

**0-31261**  
(Commission  
File Number)

**58-2108232**  
(I.R.S. Employer  
Identification Number)

**8995 Westside Parkway**  
**Alpharetta, GA 30004**  
(Address of principal executive offices)

Registrant's telephone number, including area code **(678) 336-2500**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT INDEX

EX.99.1 PRESS RELEASE DATED FEBRUARY 16, 2005

---

**Table of Contents**

**Item 2.02. Results of Operations and Financial Condition.**

On February 16, 2005, AtheroGenics, Inc. issued a press release to report the company's financial results for the fourth quarter and year ended December 31, 2004. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

The following exhibit is furnished as part of this current report on Form 8-K.

Exhibit No.	Description
99.1	Press Release dated February 16, 2005

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**ATHEROGENICS, INC.**

Date: February 16, 2005

/s/ MARK P. COLONNESE  
Mark P. Colonnese  
Senior Vice President of Finance and  
Administration and Chief Financial Officer

3

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press Release dated February 16, 2005

4